Navigation Links
TGen licenses first drug for patient use in clinical care
Date:5/4/2011

PHOENIX, Ariz. May 4, 2011 The Translational Genomics Research Institute (TGen) has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

Today's announcement is another key fulfillment of TGen's primary mission: To move laboratory discoveries more rapidly into therapeutics that can immediately help patients improve their quality of life.

The drug, ONCO-101, is being licensed to Syracuse, N.Y.-based Oncoholdings Inc., a pharmaceutical company focused on the acquisition and development of innovative anti-cancer compounds.

Oncoholdings, in turn, has contracted with a TGen subsidiary, Scottsdale-based TGen Drug Development (TD2), to help guide continued pre-clinical tests, and eventually move ONCO-101 into first-in-human clinical trials, where it could immediate help cancer patients.

"This milestone is a significant accomplishment that validates the clinical groundwork we established when forming TGen," said Dr. Jeffrey Trent, TGen President and Research Director. "Because ONCO-101 could potentially change the way patients with ovarian and endometrial cancer are treated, we hope this is but the first of many compounds that benefit patients battling life-threatening illnesses."

Licensing ONCO-101 comes nearly nine years after the establishment of TGen, an integral piece of Arizona's bioscience initiative. The goals of that initiative are to: enable scientific discoveries; improve the quality of health care, especially for Arizona residents; and diversifying the state's knowledge-based economy.

ONCO-101 was developed at TGen in the course of research into the design of drugs that selectively target key proteins involved in cancers.

TGen granted Oncoholdings the exclusive license to further develop ONCO-101, an epigenetic agent, or compound, that decides how active proteins become. Currently, there are only four epigenetic drugs on the market, and they are only approved to treat blood cancers. ONCO-101 would be the first epigenetic agent to attack solid tumors.

"This class of therapeutic agents has yet to find its place in the market for the treatment of solid tumors," according to Jeffrey Evans, Ph.D. and Chief Operating Officer of Oncoholdings. "ONCO-101 works by allowing the regular function of normal cells, while disrupting the ability of abnormal cells to reproduce, effectively stopping the cancer."

Oncoholdings expects to announce the acquisition of its second group of products in the second quarter of 2011.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. The Indiana Clinical and Translational Science Institute (CTSI) Licenses GeneGos Eureka and MetaCore Platforms
2. Cells talk more in areas Alzheimers hits first, boosting plaque component
3. Study is the first to link sleep duration to infant growth spurts
4. Cedars-Sinai to hold first annual conference on stem cell therapies for neurological disorders
5. Success of First World Congress of Pediatric Urology underscores increasing importance of specialty
6. Alzheimers diagnostic guidelines updated for first time in decades
7. University of Granada researchers make the first bioartificial organ in Spain
8. First clinical trial of gene therapy for pain reported by U-M neurologists
9. Simple chemical cocktail shows first promise for limb re-growth in mammals
10. John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
11. Study provides first link between 2 major Parkinsons genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... discovery of thousands of defective respirators, according to court documents and SEC filings. ... of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los ...
(Date:5/26/2016)... ... 2016 , ... Georgia State University College of Law is ... Answering to the increasing demand for curricular specializations, the Certificate in Intellectual Property ... land use law. ,  , “The demand for lawyers with specific knowledge in ...
(Date:5/26/2016)... ... , ... On Memorial Day, Hope For Heroes and USA Medical ... for the country. The nonprofit Hope For Heroes partnered with the leading provider ... for disabled military veterans, as well as police, firemen, and EMS professionals across the ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... that has a significant negative impact on long-term patient survival, reports a team ... results, published online this week in the Journal of Thoracic and Cardiovascular Surgery, ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... MadgeTech ... are designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With ... provide reliable monitoring solutions trusted by government agencies, including NASA. , In 2012, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016 Inivata, a global ... circulating tumour DNA (ctDNA) analysis to improve personalised ... Professor Clive Morris as Chief Medical ... clinical development programme, scientific collaborations, and through to ... improvements in clinical outcomes for patients. ...
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... -- Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... role, Marziani will lead the company,s business development and sales team, exploring new opportunities ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: